Moreover, it confirmed that intrathecal delivery of EPHA2, HER2, and IL13Rα2 CAR-T cells is an effective treatment for primary, metastatic, and recurrent group 3 medulloblastoma and PFA ependymoma in a mouse model [14]. The gene discussed is EPHA2; the disease is ependymoma.